Steph & Co. Sells 530 Shares of Teleflex Incorporated (NYSE:TFX)

Steph & Co. trimmed its position in Teleflex Incorporated (NYSE:TFX) by 73.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 192 shares of the medical technology company’s stock after selling 530 shares during the quarter. Steph & Co.’s holdings in Teleflex were worth $34,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TFX. Point72 Asset Management L.P. raised its stake in shares of Teleflex by 564.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 310,484 shares of the medical technology company’s stock valued at $65,304,000 after buying an additional 263,743 shares in the last quarter. Janus Henderson Group PLC increased its stake in Teleflex by 2.8% in the third quarter. Janus Henderson Group PLC now owns 5,376,452 shares of the medical technology company’s stock valued at $1,329,704,000 after acquiring an additional 147,147 shares during the period. FMR LLC raised its position in Teleflex by 70.1% in the third quarter. FMR LLC now owns 269,490 shares of the medical technology company’s stock worth $66,650,000 after purchasing an additional 111,086 shares in the last quarter. Kimelman & Baird LLC bought a new position in Teleflex during the second quarter worth about $21,232,000. Finally, Assenagon Asset Management S.A. boosted its holdings in Teleflex by 457.6% during the third quarter. Assenagon Asset Management S.A. now owns 120,311 shares of the medical technology company’s stock valued at $29,755,000 after purchasing an additional 98,735 shares in the last quarter. 95.62% of the stock is owned by institutional investors.

Teleflex Stock Up 2.7 %

Shares of NYSE TFX opened at $181.41 on Friday. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. The company has a market cap of $8.42 billion, a price-to-earnings ratio of 36.06, a price-to-earnings-growth ratio of 1.64 and a beta of 1.16. Teleflex Incorporated has a 12-month low of $171.69 and a 12-month high of $256.85. The firm’s 50-day simple moving average is $184.42 and its 200 day simple moving average is $215.64.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.38 by $0.11. The company had revenue of $764.40 million for the quarter, compared to analyst estimates of $768.68 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. Teleflex’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.64 earnings per share. On average, research analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were paid a $0.34 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.36 annualized dividend and a dividend yield of 0.75%. Teleflex’s dividend payout ratio (DPR) is currently 27.04%.

Analyst Ratings Changes

TFX has been the subject of a number of recent research reports. Royal Bank of Canada dropped their target price on Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Mizuho dropped their price objective on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. StockNews.com upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Finally, Truist Financial cut their price target on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $252.50.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.